A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. uri icon

Overview

publication date

  • February 7, 2008

Research

keywords

  • Cancer Vaccines
  • Fusion Proteins, bcr-abl
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Identity

Scopus Document Identifier

  • 49449115889

Digital Object Identifier (DOI)

  • 10.1038/leu.2008.7

PubMed ID

  • 18256684

Additional Document Info

volume

  • 22

issue

  • 8